FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO) is a website specializing in disseminating information on life science AI."FRONTEO Life Science AI Business Academy"Will be opened.On this site, in addition to the latest information on AI development and utilization centered on natural language analysis in the fields of medical care and drug discovery, as well as specialized information such as electronic medical records and dissertation information, patients and consumers who have been attracting attention in recent years We will disseminate cutting-edge information on themes such as data-driven market and AI utilization based on healthcare-related data in the real world (world outside medical institutions).

 

　In addition to key opinion leaders in the fields of artificial intelligence and life science, we invite instructors from a wide range of fields, such as those involved in companies developing products equipped with AI, to disseminate information from various perspectives.In addition, we will contribute to the realization of medical DX and the solution of social issues, the promotion of digital medical care, and the improvement of the quality and efficiency of medical care by utilizing our unique natural language AI.

 

　As the first step, we will hold the following webinar.

 

◆ Seminar outline
theme:Data-driven market trends and future vision in the medical field
　　　　-New solutions utilizing AI and industry game changers-
Teacher:Masato Takahashi (FRONTEO Inc. Executive Officer / General Manager of Life Science AI Business Headquarters)
Date:[Livestream] April 2022, 4 (Wednesday) 13: 18-15: 18
　　　　[Recorded distribution] April 2022, 4 (Thursday) 14: 12-15: 12
venue:WEB held (URL will be sent after application)
Entry fee:Free
agenda:
　In the medical field such as the spread of mobile terminals such as smartphones, the spread of communication-type apps such as SNS, the spread of electronic medical records, the expansion of telemedicine, and the utilization of real-world data amid the progress of the information-oriented society worldwide. In Japan, the introduction of AI and the trend of digitalization are accelerating rapidly.On the other hand, in addition to the progress of AI technology, there are problems with software and communication networks, and complicated regulations unique to the industry, so the current situation is that the number of AI solutions that have been put into practical use in the medical and pharmaceutical fields is still limited. ..
In this lecture, in addition to the latest trends in the data-driven market in the medical industry, we will introduce the development of program medical devices centered on AI and the future image of the industry, based on specific examples.
How to Request:[4/13]https://lifescience.fronteo.com/ba/knobbe/webinar0413
　　　　　　[4/14]https://lifescience.fronteo.com/ba/knobbe/webinar0414

 

　FRONTEO has been developing solutions for AI medical devices and software in the life science field, using the artificial intelligence "Concept Encoder (trademark: conceptencoder, reading: concept encoder)" developed in-house as its core technology.Going forward, we will continue to work on research and development and information dissemination toward the more effective use of AI in medical and research settings and the realization of medical DX.

 

■ About Concept Encoder　URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engines "KIBIT", "Concept Encoder", and "Looca Cross" that specialize in natural language processing to extract meaningful and important information from a huge amount of text data, and is a company. It is a data analysis company that supports the business of. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support corporate international litigation. Has been deployed.Based on the AI ​​technology cultivated in this business, we will expand the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge", We contribute to solving various corporate issues such as drug discovery support, dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers on June 2014, 2007. Obtained a first-class medical device manufacturing and sales business license in January 6 (permit number: 26B2021X1), and notified the managed medical device sales business in September of the same year (notification number: 13 Minato Misei Equipment No. 1).The capital is 10350 thousand yen (as of March 9, 3).

* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.